The authors examined the mortality rate in geriatric patients receiving either haloperidol or atypical antipsychotics.Methods
Authors tracked mortality over a 2-year period in patients age 65 years or older receiving haloperidol (N=299) or the atypical antipsychotics risperidone or olanzapine (N= 1,254).Results
Sixty-four patients in the haloperidol group (21.4%) and 61 patients in the atypical group (4.75%) died during the 2-year study period. The difference was statistically significant.Conclusions
The findings suggest that mortality in elderly patients receiving haloperidol is significantly higher than in those receiving the atypical antipsychotics risperidone or olanzapine. Authors discuss possible causal mechanisms.